Human Bioequivalence Test of Liraglutide Injection
2021年8月30日 更新者:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
To evaluate the bioequivalence of The liraglutide injection produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Victoza® produced by Novo Nordisk (China) Pharmaceutical Co., Ltd for single dose in healthy subjects,so as to provide reference for clinical evaluation and clinical medication;To observe the safety of the test preparation liraglutide injection and the reference preparation Victoza ® in healthy subjects.
研究概览
研究类型
介入性
注册 (实际的)
28
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Jilin
-
Changchun、Jilin、中国、130021
- Affiliated Hospital of Changchun University of Traditional Chinese Medicine
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 60年 (成人)
接受健康志愿者
是的
有资格学习的性别
全部
描述
Inclusion Criteria:
- Sign the informed consent form before the trial, fully understand the trial purpose, process and possible adverse reactions;
- Able to complete the study according to the requirements of protocol;
- Aged between 18 and 60 years old, both men and women;
- Male ≥50kg, female ≥45kg,body mass index(BMI)=weight (kg)/height 2 (m2), BMI is 18-28 kg/m2 (including the critical value);
- No mental abnormalities, no history of cardiovascular system, nervous system, respiratory system, digestive system, urinary system, endocrine system or metabolic abnormalities;
- Normal or abnormal vital signs, physical examination, laboratory examination, electrocardiogram, and imageological examination have no clinical significance;
- The female blood pregnancy test is not pregnant, and the subjects (including male subjects) have no pregnancy plan and voluntarily take effective contraceptive measures from 2 weeks before administration to at least 3 months after the last use of the study drug. See the appendix for specific contraceptive measures.
Exclusion Criteria:
- Previous disease of the neuropsychiatric system, respiratory system, cardiovascular system, digestive system, hemo-lymphatic system, liver and kidney dysfunction, endocrine system, musculoskeletal system, or other disease that the investigator determines may affect drug metabolism or safety;
- Have a history of fainting needles, fainting blood;
- Known allergy to Liraglutide and its metabolites or any of the excipients of the formulation;
- Those who smoked more than 5 cigarettes per day during the 3 months before the trial.
- History of drug and/or alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 360 ml of beer or 45 ml of 40% alcoholic spirits or 150 ml of wine);
- Donated blood or lost a lot of blood (> 450 ml) within 2 months before taking the study drug ;
- Have taken any drug that changes liver enzyme activity 28 days before taking the study drug (such as liver drug enzyme inhibitor chlorpromazine, cimetidine, ciprofloxacin, metronidazole, etc.; liver drug enzyme inducer barbital Drugs, carbamazepine, rifampicin, dexamethasone, etc.);
- Have taken any prescription, over-the-counter, vitamin product or herbal medicine within 1 month prior to the use of the study drug;
- During the trial it is necessary to use tobacco, alcohol, and caffeine-containing drinks, or certain foods that may affect metabolism (such as grapefruit, grapefruit juice, etc.), or major changes in diet or exercise habits before the test, or other effects that affect drug absorption, Factors such as distribution, metabolism, excretion, etc;
- Have taken the study drug or participated in the drug clinical trial within 2 months before taking the study drug;
- Positive for hepatitis (including hepatitis B and C), HIV or syphilis at screening;
- Female subjects are breastfeeding or have a positive serum pregnancy result during the screening period or during the test;
- Those who have been screened positive for drugs or have a history of drug abuse in the past five years or have used drugs in the 3 months before the trial;
- Blood collection is difficult or cannot tolerate venipuncture blood collection;
- Acute illness during the screening phase or before study medication;
- The subject is unable or can not comply with ward management regulations;
- The subject is unable to complete the study due to personal reasons;
- Other cases judged by researchers to be unsuitable for selection.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Liraglutide injection + Victoza
Subjects receive liraglutide injection in the first cycle and Victoza in the second cycle.
|
Human glucagon-like peptides-1 analogue
Human glucagon-like peptides-1 analogue
|
实验性的:Victoza +Liraglutide injection
Subjects receive Victoza in the first cycle and liraglutide injection in the second cycle.
|
Human glucagon-like peptides-1 analogue
Human glucagon-like peptides-1 analogue
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Maximum (peak) plasma drug concentration(Cmax)
大体时间:0 hour(pre-dose,within 60mins) to 72hours after administration on day1 and day 15.
|
Maximum (peak) plasma drug concentration
|
0 hour(pre-dose,within 60mins) to 72hours after administration on day1 and day 15.
|
Time to reach maximum (peak) plasma concentration following drug administration (Tmax)
大体时间:0 hour(pre-dose,within 60mins) to 72hours after administration on day1 and day 15.
|
Time to maximum concentration
|
0 hour(pre-dose,within 60mins) to 72hours after administration on day1 and day 15.
|
Area under the plasma concentration-time curve from time zero to time t (AUC0-t)
大体时间:0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
The area under the plasma concentration curve from 0 to infinity
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Terminal disposition rate constant/terminal rate constant (λz)
大体时间:0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent end elimination rate constant
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Elimination half-life (t1/2)
大体时间:0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
The time required for the highest concentration of the drug in plasma to decrease by half
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent total clearance of the drug from plasma after oral administration (CL/F)
大体时间:0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent total body clearance
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent volume of distribution after non-intravenous administration (Vd/F)
大体时间:0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Apparent volume of distribution
|
0 hour(pre-dose, within 60 mins) to 72 hours after administration on day1 and day 15.
|
Bioavailability (systemic availability of the administered dose)
大体时间:0 hour(pre-dose, within 60mins) to 72 hours after administration on day1 and day 15.
|
Relative bioavailability
|
0 hour(pre-dose, within 60mins) to 72 hours after administration on day1 and day 15.
|
Adverse Event, Serious Adverse Event and Drug Combination
大体时间:up to day 15
|
Monitor the safety indicators of subjects during the trial
|
up to day 15
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
body temperature
大体时间:1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
abnormal body temperature
|
1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
pulse
大体时间:1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
abnormal pulse
|
1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
blood pressure
大体时间:1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
abnormal blood pressure
|
1 hour before administration and 2 hours, 10 hours, 24 hours, 48 hours, 72 hours after administration on day 1 and day 15
|
clinical symptoms
大体时间:From the screening period to day 18 after the first administration
|
Any discomfort spontaneously reported by the subject
|
From the screening period to day 18 after the first administration
|
The Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (physical examination)
大体时间:From the screening period to day 18 after the first administration
|
Monitor the safety indicators of subjects during the trial,For example: skin, mucous membrane, head (head, eyes, ears, nose, mouth), neck, chest (chest, breast, lung, heart), abdomen (liver, gallbladder, spleen, kidney, bladder), spine, limbs, nervous system, lymph nodes, etc,and calculate the Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
|
From the screening period to day 18 after the first administration
|
The Number of participants with abnormal laboratory examinations
大体时间:From the screening period to day 18 after the first administration
|
laboratory examination, such as liver function, kidney function, coagulation function, blood routine, urine routine
|
From the screening period to day 18 after the first administration
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2019年5月21日
初级完成 (实际的)
2019年6月1日
研究完成 (实际的)
2019年7月1日
研究注册日期
首次提交
2021年8月24日
首先提交符合 QC 标准的
2021年8月30日
首次发布 (实际的)
2021年8月31日
研究记录更新
最后更新发布 (实际的)
2021年8月31日
上次提交的符合 QC 标准的更新
2021年8月30日
最后验证
2021年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
2型糖尿病的临床试验
-
Jin-Hee AhnAsan Medical Center未知HER-2基因扩增 | HER-2 蛋白过表达
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.未知
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.主动,不招人
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical Co...主动,不招人
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and Arts完全的
Liraglutide injection的临床试验
-
Kaohsiung Medical University Chung-Ho Memorial...Tri-Service General Hospital招聘中